Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe E Gatt

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Annals of Hematology|March 12, 2026
Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosisTamir Shragai, Muhammad Ganayem, Yael C Cohen, et al.
Haematologica|March 31, 2022
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaOrtal Harush, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
American Journal of Hematology|November 3, 2016
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapyAdir Shaulov, Chezi Ganzel, Noam Benyamini, et al.
Acta Haematologica|October 2, 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the LiteratureEyal Lebel, Vladimir Vainstein, Paolo Milani, et al.
Acta Haematologica|August 7, 2022
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid LeukemiaBoaz Nachmias, Svetlana Krichevsky, Dvora Filon, et al.
Haematologica|June 29, 2023
Amyloidogenic light chains impair plasma cell survivalMarjorie Pick, Eyal Lebel, Sharona Elgavish, et al.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
European Journal of Haematology|December 24, 2022
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myelomaOded Shamriz, Elchanan Parnasa, Limor Rubin, et al.
Cancers|March 29, 2023
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World StudyEyal Lebel, Efstathios Kastritis, Giovanni Palladini, et al.
Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Annals of Hematology|March 12, 2026
Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosisTamir Shragai, Muhammad Ganayem, Yael C Cohen, et al.
Haematologica|March 31, 2022
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaOrtal Harush, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
American Journal of Hematology|November 3, 2016
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapyAdir Shaulov, Chezi Ganzel, Noam Benyamini, et al.
Acta Haematologica|October 2, 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the LiteratureEyal Lebel, Vladimir Vainstein, Paolo Milani, et al.
Acta Haematologica|August 7, 2022
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid LeukemiaBoaz Nachmias, Svetlana Krichevsky, Dvora Filon, et al.
Haematologica|June 29, 2023
Amyloidogenic light chains impair plasma cell survivalMarjorie Pick, Eyal Lebel, Sharona Elgavish, et al.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
European Journal of Haematology|December 24, 2022
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myelomaOded Shamriz, Elchanan Parnasa, Limor Rubin, et al.
Cancers|March 29, 2023
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World StudyEyal Lebel, Efstathios Kastritis, Giovanni Palladini, et al.
Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.
Pageof 9